Shah Pratik 4
4 · Design Therapeutics, Inc. · Filed Sep 5, 2023
Insider Transaction Report
Form 4
Shah Pratik
DirectorPresident, CEO and Chairperson
Transactions
- Award
Stock Option (right to buy)
2023-09-01+525,000→ 525,000 totalExercise: $2.48Exp: 2033-08-31→ Common Stock (525,000 underlying) - Award
Stock Option (right to buy)
2023-09-01+1,050,000→ 1,050,000 totalExercise: $2.48Exp: 2033-08-31→ Common Stock (1,050,000 underlying) - Award
Stock Option (right to buy)
2023-09-01+525,000→ 525,000 totalExercise: $2.48Exp: 2033-08-31→ Common Stock (525,000 underlying)
Footnotes (3)
- [F1]The shares subject to the option will vest as follows: 25% of the shares subject to the option will vest one year following August 25, 2023, and thereafter the balance of the shares will vest in equal monthly installments over the following 36 months.
- [F2]The shares subject to the option will vest as follows provided that an investigational new drug application for a product candidate for the treatment of Friedrich ataxia ("FA") submitted by the Issuer after September 1, 2023 receives clearance from the U.S. Food and Drug Administration: 25% of the shares subject to the option will vest one year following August 25, 2023, and thereafter the balance of the shares will vest in equal monthly installments over the following 36 months.
- [F3]The shares subject to the option will vest as follows provided that the Company initiates a Phase 2a clinical trial for a product candidate for the treatment of FA: 25% of the shares subject to the option will vest one year following August 25, 2023, and thereafter the balance of the shares will vest in equal monthly installments over the following 36 months.